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Aim To evaluate four different commercially available as-
says for anti-double stranded DNA (dsDNA) detection and 
compare them with the in-house radioimmunoassay ac-
cording to Farr (FARR-RIA) in order to select the optimal pri-
mary method for use in combination with FARR-RIA.
Methods Sera from 583 consecutive patients sent to our 
laboratory for routine diagnosis, 156 selected patients with 
autoimmune diseases (76 systemic lupus erythematosus 
[SLE] patients and 80 patients with other autoimmune dis-
eases), and 150 blood donors were tested for anti-dsDNA 
antibodies with two enzyme-linked immunoassays (ELISA), 
two  Crithidia  luciliae  immunoflourescence  tests  (CLIFT), 
and FARR-RIA. The specificities and sensitivities of the tests 
were calculated and compared.
Results FARR-RIA and CLIFT 2 showed the highest speci-
ficity for SLE (100%), with CLIFT 2 showing higher sensi-
tivity (33% vs 47%). Both ELISAs showed higher sensitivi-
ties (>53%) than FARR-RIA but lower specificities (<93%), 
whereas  CLIFT  1  showed  the  lowest  overall  agreement 
with FARR-RIA.
Conclusion CLIFT 2 was selected as the primary test for 
use in combination with FARR-RIA. The use of CLIFT 2 re-
duced the number of sera that needed to be tested by 
FARR-RIA, the time needed to report the results, and envi-
ronmental toxicity, cancerogenicity, and radioactivity.
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Anti-double stranded (dsDNA) antibodies were discovered 
in 1957 and since then have been well recognized as di-
agnostic markers of systemic lupus erythematosus (SLE). 
They are excellent indicators of SLE disease activity (1,2) 
and their elevated levels usually precede exacerbation of 
disease (sometimes by more than a year) (3). Anti-dsDNA 
levels rise during flares of SLE disease activity, especially in 
lupus nephritis (3,4). Many studies questioned the signifi-
cance of anti-dsDNA antibodies in disease pathology and 
the association between anti-dsDNA antibodies and dis-
ease activity using a variety of different assays (5-9).
Anti-dsDNA antibodies are generally detected and quan-
tified  by  commercially  available  kits  for  enzyme-linked 
immunosorbant  assay  (ELISA,  also  automated  versions), 
Crithidia luciliae  immunofluorescence  assay  (CLIFT),  and 
radioimmunoassay methods developed according to Farr 
technique (FARR-RIA) (9). Different combinations of these 
methods are used in diagnostic laboratories worldwide, 
without a consensus on exclusive methods (8,10). An im-
portant cause of discrepancies between results obtained 
with different methods lies in the avidity of antibodies. ELI-
SAs detect antibodies of both low and high avidity, where-
as CLIFT and FARR-RIA assays predominantly detect anti-
bodies of high avidity (11). The method of choice in our 
diagnostic laboratory since the 1970s has been FARR-RIA. 
This technique was introduced by Wold et al in 1968 (12) 
and it employs ammonium sulfate precipitation to sepa-
rate  dsDNA/anti-dsDNA  complexes  from  free  (radiola-
beled) dsDNA. In our assay we use commercially available 
14C labeled dsDNA from E. Coli.
There are certain considerations regarding the detection 
of anti-dsDNA antibodies that need to be specified. For the 
diagnosis of SLE, it is crucial that the anti-dsDNA assay is 
highly specific for dsDNA, especially since elevated levels 
of anti-dsDNA antibodies can also be detected in other au-
toimmune diseases, as well as in blood donors, very much 
depending on the detection method used (13-17). FARR-
RIA has the highest specificity for anti-dsDNA antibodies 
detection but a low sensitivity (18). Therefore, the practical 
approach has been to use an assay that detects both high 
and low avidity anti-dsDNA antibodies as a primary screen 
(19). Such an assay is either CLIFT (20) or anti-dsDNA ELISA 
(15). When using CLIFT, it is extremely important to score 
only the kinetoplast fluorescence since nuclei always con-
tain many antigens other than DNA (5). Retesting of posi-
tive samples with FARR-RIA not only confirms the diagnosis 
but also provides the quantitative data allowing the physi-
cian to monitor disease activity (8). The problem with anti-
dsDNA ELISAs is that they often give false-positive results 
due  to  binding  of  immune  complexes  (with  negatively 
charged moieties) to the pre-coat intermediates (10,11). 
An alternative to classic ELISA makes use of biotinylated 
DNA coating via streptavidin to the plates; however the de-
tection of antibodies against single-stranded DNA remains 
another deficiency of these tests (19). Antibodies against 
single-stranded DNA only recognize single-stranded DNA 
and are specifically directed against purine and pyrimidine 
bases (21). They are observed not only in patients with SLE 
but also in other connective tissue diseases, such as sys-
temic sclerosis and myositis (11).
The aim of our study was to evaluate four different com-
mercially  available  assays  for  anti-dsDNA  detection  and 
compare them to the in-house FARR-RIA assay in sera from 
583  consecutively  collected  individuals,  156  individuals 
with autoimmune diseases, and 150 blood donors. The 
overall intent was to substantially shorten the time of re-
porting results, lower toxicity, and estimate the overall lab-
oratory costs for anti-dsDNA testing.
MATeriALS And MeThodS
Participants
This cross-sectional study analyzed 156 sera of Slovene 
patients with systemic autoimmune diseases. Seventy-six 
patients (5 men and 71 women, mean age 40.49 ± 11.7) 
with  SLE  fulfilled  the  criteria  established  by  American 
Rheumatism Association (22) and revised by the Ameri-
can College of Rheumatology (23). The patients’ control 
group of 80 patients (14 men and 66 women, mean age 
51.74 ± 13.6)  comprised  16  patients  with  primary  an-
tiphospholipid  syndrome  (pAPS)  who  were  diagnosed 
based  on  the  revised  International  Consensus  criteria 
(24), 35 patients with rheumatoid arthritis, and 29 patients 
with Sjoegren’s syndrome. All patients had their sera col-
lected and analyzed at the Department of Rheumatology, 
University Medical Centre, Ljubljana. In addition, we in-
cluded consecutive sera of 583 Slovenians that were sent 
to our laboratory for anti-dsDNA testing from April to July 
2009 and the diagnoses/clinical signs of these individu-
als were unknown to us at the time of the measurements 
(141 men and 442 women, mean age 46.54 ± 18.8). The 
donor control group included sera from 150 blood do-
nors (93 men and 57 women, mean age 42.64 ± 11.6). All 
sera were collected in May 2009, aliquoted, tested by 
the FARR-RIA in 48 hours and the rest of the sera were 
stored at -80°C until assayed by ELISAs and CLIFTs. BASIC SCIENCE 696 Croat Med J. 2011; 52: 694-702
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Participants signed an informed consent and the study 
was approved by the National Medical Ethics Committee, 
Ljubljana, Slovenia.
Laboratory measurements
Patient sera were prospectively analyzed with five different 
anti-dsDNA assays. Four of them were commercially avail-
able kits. We used two indirect immunofluorescent tests 
– NOVA LiteTM dsDNA Crithidia luciliae (INOVA Dignostics, 
San Diego, CA, USA) (CLIFT 1) and Fluorescent nDNA Test 
system (Immuno Concepts, Sacramento, CA, USA) (CLIFT 2) 
and two enzyme immunoassays – DiastatTM (Euro-Diagnos-
tica, Malmö, Sweden) (ELISA 1) and Quanta LiteTM dsDNA 
(INOVA Dignostics) (ELISA 2). All kits were used according 
to the manufacturer’s instructions. All CLIFT preparations 
were examined by three biochemical analysts in order to 
obtain a consensus result. The analysts were blinded to the 
results of other tests or other clinical information.
The in-house FARR-RIA method used in the Immunology 
Laboratory since 1976 follows the first published proto-
col (25) with some adaptations. Briefly, sera complement 
was inactivated by heating at 56°C for 30 minutes. Five mi-
croliters of sera were diluted (1:10) in borate buffer saline 
(pH = 8.0) in a glass tube and incubated with 100 ng 14C 
dsDNA extracted from E coli (Amersham Pharmacia Biotek, 
Little Chalfont, UK) for 1 hour at 37°C. Samples were stored 
overnight at 4°C, and the following day saturated ammo-
nium sulfate was added to precipitate proteins (1:1) and 
incubated for one hour at 4°C. Following a 15-minute-cen-
trifugation at 1800 × g, the supernatants (S) and pellets (P) 
were divided into separate glass bottles for scintillation 
counting. Bray scintillation solution was added, and the 
amount of radiation (cpm counts) was measured in each 
flask. The ratio (P-S/P+S) above 0.35 was determined as a 
positive result.
The international reference standard WO/80 was no longer 
available from the World Health Organization and there-
fore it was not included in the study.
Statistical analysis
Statistical analysis was performed using the SPSS 15.0 pro-
gram (SPSS Inc., Chicago, IL, USA). Correlations of variables 
were determined by the Spearman rank correlation, and 
kappa values for agreement were computed. Normality of 
distribution was evaluated with Kolmogorov-Smirnov test, 
normal probability plots, and curve fittings. Since data were 
not normally distributed, differences between the means 
were analyzed by the Mann-Whitney test. The relative risks 
were approximated by odds ratios with its 95% confidence 
interval. The receiver operating characteristic curves (ROC) 
were constructed, and sensitivity, specificity, and positive 
and negative predictive values were calculated. A P value 
of <0.05 was considered statistically significant.
reSuLTS
normal range and cut-off values for anti-dsdnA assays
The main characteristics of the five anti-dsDNA assays are 
presented in Table 1. The reference range of the assays was 
determined by analyzing samples from 150 blood donors. 
None of the anti-dsDNA results fulfilled the criteria of nor-
mal distribution with Kolmogorov-Smirnov test (P < 0.001). 
In ELISA 1, the 99th percentile estimated on our popula-
tion was on the border between equivocal and positive 
samples as determined by the manufacturer and in ELISA 





donors (n = 150)
Assay Manufacturer Method detection dsdnA origin and positive† 99th percentile mean±2Sd
ELISA 1 Euro-Diagnostica microplate/manual IgG, IgM calf thymus dsDNA   50 IU/mL   50.2 18.7
ELISA 2 INOVA Dignostics microplate/manual IgG calf thymus dsDNA 300 IU/mL 177.3 87.7
FARR-RIA in house RIA/manual IgG, IgM [14C] DNA extract 
from E. coli
  0 . 3 5   0.11 0.12
CLIFT 1 INOVA Dignostics CLIFT/manual IgG kinetoplast DNA presence of fluorescence at kinetoplast for a serum 
dilution at 1/10
CLIFT 2 Immuno Concepts CLIFT/manual IgG kinetoplast DNA presence of fluorescence at kinetoplast for a serum 
dilution at 1/10
*Abbreviations: Sd – standard deviation; iu – international units; eLiSA – enzyme-linked immunoassays; FArr-riA – radioimmunoassay according to 
Farr; CLiFT – Crithidia luciliae immunoflourescence test.
†According to the manufacturer.697 Žigon et al: Detection of anti-dsDNA antibodies
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2 it was lower than the manufacturer’s, however their cal-
culations included more blood donors.
The cut-off value for FARR-RIA anti-dsDNA antibody posi-
tivity has been previously determined to be 0.33 (20). Two 
parameters of frequency distribution (99th percentile and 
mean +2SD) for FARR-RIA results are presented in Table 1. 
In accordance with our clinical parameters, we set the cut-
off value at 0.35 using the diagnostic specificity of 100%. 
CLIFT 1 found 8 weakly positive and 3 highly positive blood 
donors, while CLIFT 2 and FARR-RIA found all blood donors 
to be negative.
TAbLe 2. detection of anti-double stranded dnA (dsdnA) antibodies by five different assays in 583 sera sent to immunology labora-
tory for routine anti-dsdnA testing*
no. of patients (cut-off values)†
Assay‡ negative equivocal weakly positive moderately positive highly positive
CLIFT 1 401 (-) / 79 (+) 99 (++)   4 (+++)
CLIFT 2 513 (-) / 28 (+) 31 (++) 11 (+++)
FARR-RIA 558 (<0.35) / 3 (0.35-0.39) 12 (0.40-0.55) 10 (>0.55)
ELISA 1 (IU/mL) 487 (<30) 16 (31-50) 69 (51-300) / 11 (>300)
ELISA 2 (IU/mL) 500 (<200) 23 (201-300) 44 (301-800) / 16 (>800)
*Abbreviations: eLiSA – enzyme-linked immunoassays; FArr-riA – radioimmunoassay according to Farr; CLiFT – Crithidia luciliae immunofloures-
cence test.
†The cut-off values, presented in parentheses, were determined according to the manufacturer instructions for CLiFT and eLiSA.
TAbLe 3. Correlation of four commercial kits for detection of anti-double stranded dnA (dsdnA) antibodies and the in-house FArr-
riA in 583 sera sent to immunology laboratory for routine anti-dsdnA testing*
CLiFT 1 CLiFT 2 eLiSA 1 eLiSA 2
- + - + - + - +
FArr-riA
- 401 158 511 48 499 60 519 40
+   0   24   2 22   4 20   4 20
Spearman coefficient; P     0.31; <0.001     0.51; <0.001     0.42; <0.001   0.50; <0.001
overall agreement (%)   73   91   89 92
Kappa†   0 . 1 7 3   0 . 4 3 3   0 . 3 4 3   0.443
*Abbreviations: eLiSA – enzyme-linked immunoassays; FArr-riA – radioimmunoassay according to Farr; CLiFT – Crithidia luciliae immunofloures-
cence test.
†Kappa – Cohen’s kappa coefficient, a statistical measure of agreement.
TAbLe 4. diagnostic specificity and sensitivity for systemic lupus erythematosus obtained with four different anti- double stranded 
























CLIFT 1 - 35 14 <0.001 3.4 81.6   43.8   57.9 71.4 1.5 0.4
+ 45 62
CLIFT 2 - 80 40 <0.001 -‡ 47.4 100.0 100.0 66.7 -‡ 0.5
+  0 36
FARR-RIA - 80 51 <0.001 -‡ 32.9 100.0 100.0 61.1 -‡ 0.7
+  0 25
ELISA 1 - 73 29 <0.001 16.9 61.8   91.3   87.0 71.6 7.1 0.4
+  7 47
ELISA 2 - 74 35 <0.001 14.5 53.9   92.5   87.2 67.9 7.2 0.5
+  6 41
*Abbreviations: eLiSA – enzyme-linked immunoassays; FArr-riA – radioimmunoassay according to Farr; CLiFT – Crithidia luciliae immunofloures-
cence test.
†rheumatoid arthritis, Sjoegren syndrome, and primary antiphospholipid syndrome.
‡no false positives detected.BASIC SCIENCE 698 Croat Med J. 2011; 52: 694-702
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Comparison of four commercially available tests and in-
house FArr-riA
We used 583 fresh sera from persons who underwent anti-
dsDNA testing in our Immunology Laboratory. Their diag-
noses/clinical signs were unknown to us at the time of the 
measurements. We determined the levels of anti-dsDNA 
with four different assays and compared the results with 
those obtained by FARR-RIA. CLIFT 1 detected the greatest 
number of positive sera, while FARR-RIA detected the low-
est number of positive sera (Table 2).
There was an overall agreement between CLIFT 2 and ELI-
SA 2 with FARR-RIA of above 90%, and a low agreement 
between CLIFT 1 and FARR-RIA (73%) (Table 3).
The levels of anti-dsDNA antibodies detected with both 
quantitative ELISA anti-dsDNA methods significantly cor-
related  with  FARR-RIA  (Spearman  rank  correlation  co-
efficient,  (Rho = 0.491  –  ELISA  1,  Rho = 0.418  –  ELISA  2; 
P < 0.001) (Figure 1).
diagnostic accuracy of FArr-riA as compared with four 
commercially available anti-dsdnA kits
FARR-RIA and CLIFT 2 showed the highest specificity for 
SLE (100%) (Table 4). No false positives were determined 
by either of the assays, which indicates the absence of 
SLE. CLIFT 2 detected 47.4% of all SLE patients, meaning 
that it was more sensitive than FARR-RIA. Both ELISAs had 
higher sensitivity than FARR-RIA when the manufacturers’ 




Time for reporting 
(% of FArr-riA)‡ Toxic/cancerogenous chemicals§
CLIFT 1 50 20 0.09% NaN3 as a preservative
CLIFT 2 50 20 0.09% NaN3 as a preservative
ELISA 1 75 50 0.5% NaN3 in wash buffer and sample diluents, phenolphthalein monophosphate, 
bronidox L, diethanolamin in substrate, NaOH in stop solution
ELISA 2 75 50 0.5% NaN3 as preservative, 0.02% chloramphenicol in sample diluents, poisonous/
corrosive chemical in conjugate, irritant in substrate, H2SO4 in stop solution
FARR-RIAII 100 100 14C labeled DNA, Bray scintillation fluid: 2.5-diphenyloxazole, naphthalene, metha-
nol, dioxan, ethylene glycol
*Abbreviations: eLiSA – enzyme-linked immunoassays; FArr-riA – radioimmunoassay according to Farr; CLiFT – Crithidia luciliae immunofloures-
cence test.
†Personnel, reagent, and laboratory maintenance costs.
‡Time between the arrival of the sample in the laboratory and reporting the rsult back to the clinicians.
§The qualitative description of all toxic agents used in the particular anti-dsdnA test.
iiThe arbitrary scoring scale was set at 100 for FArr-riA and all other tests were compared to FArr-riA in percentages.
Figure 1.
Anti-double stranded dnA antibodies detected with in-house radioimmunoassay according to Farr correlated significantly with results of both enzyme-
linked immunoassays, eurodiagnostica diastat™ (left panel) and eiA inoVA Quanta Lite™ dsdnA (right panel) in 583 sera sent to immunology laboratory 
for routine anti-dsdnA testing.699 Žigon et al: Detection of anti-dsDNA antibodies
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cut offs were considered. However, both of them showed 
a  lower  diagnostic  specificity  and  consequently  lower 
positive predictive value than FARR-RIA. Setting the cut-
off at the 99th percentile estimated on our donors’ con-
trol population would even lower the diagnostic speci-
ficity of the ELISAs, therefore these calculations were not 
considered. CLIFT 1 showed the highest sensitivity, but 
since it had the lowest specificity (with the positive likeli-
hood ratio close to 1), this had little practical significance 
(Table 4).
We evaluated the diagnostic applicability of all assays with 
ROC curve and estimated the area under the curve (Fig-
ure 2). The greatest area under the curve was obtained for 
ELISA 1 and the smallest for both CLIFT assays, partially be-
cause they are qualitative assays. FARR-RIA area under the 
curve was between ELISA and CLIFT, because its cut-off 
was set for high specificity and consequently lower sen-
sitivity (Figure 2).
CLIFT 2 and FARR-RIA detected only SLE patients as posi-
tive for anti-dsDNA. All the other kits also detected patients 
with pAPS, rheumatoid arthritis, and Sjoegren syndrome 
(false positives) (Figure 3).
overall costs, time of reporting, and toxic/cancerous 
effects of commercially available tests and FArr riA.
Four tests and FARR-RIA (100%) were compared according 
to the total costs, time needed for reporting the results, en-
vironmental  toxicity,  and  cancerogenous  characteristics. 
FARR-RIA was most cancerogenous and toxic to the envi-
ronment, had the longest time needed for reporting the 
results, and was most costly. It also requires special safety 
measures, training of laboratory personnel, and manage-
ment of workplace and radioactive waste. CLIFT and ELISA 
tests showed substantial improvement in all of these cat-
egories. Specifically, cost benefits of CLIFT tests and ELISA 
were respectively 50% and 25% higher than those of FARR-
RIA. Also, their time needed for reporting the results after 
having received the samples was respectively one fifth and 
one half shorter than that required by FARR-RIA (Table 5).
diSCuSSion
We determined that CLIFT 2 was the most suitable method 
for anti-dsDNA detection in combination with FARR-RIA. 
Both CLIFT tests showed higher sensitivity than FARR-RIA 
and CLIFT 2 showed a higher specificity and a much higher 
overall agreement with FARR-RIA without losing any tru-
ly positive samples. However, CLIFT as a qualitative assay 
Figure 2.
Correlation  between  specificity  and  sensitivity  of  four  anti-double 
stranded dnA kits and in-house radioimmunoassay according to Farr 
(FArr-riA). Area under the curve values were the following: Crithidia lu-
ciliae immunoflourescence test (CLiFT) 1 – 0.771; CLiFT 2 – 0.737; FArr-
riA – 0.787; enzyme-linked immunoassays (eLiSA) 1 – 0.835; eLiSA 2 – 
0.789.
Figure 3.
Levels of anti-double stranded dnA (dsdnA) antibodies in patients groups with primary antiphos-
pholipid syndrome (open bars), systemic lupus erythematosus (light gray bars), rheumatoid arthri-
tis (dark gray bars), and Sjoegren syndrome (closed bars) detected by four anti-dsdnA kits and in-
house radioimmunoassay according to Farr (FArr-riA). dashed lines represent the cut-off value for 
each individual assay. in order to present all methods in one graph, the results were recalculated 
based on the following: for Crithidia luciliae immunoflourescence test (CLiFT) kits, semiquantita-
tive levels were multiplied by 100, for FArr-riA the ratio values were multiplied by 1000, and for 
enzyme-linked immunoassays (eLiSA) kit values were unchanged (iu/mL).BASIC SCIENCE 700 Croat Med J. 2011; 52: 694-702
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cannot substitute FARR-RIA, but can reduce its use by ap-
proximately 80%, since the results of 583 consecutive sera 
showed that only every 10th to 15th patient was tested 
positive for anti-dsDNA by CLIFT and needed quantitative 
confirmation by FARR-RIA.
For both ELISAs, as qualitative assays, we determined the 
reference range and cut-off values in our population of 
blood  donors.  Their  diagnostic  specificities  were  lower 
than those of FARR-RIA. Our calculations of 99th percentile 
set the cut-off values lower than the manufacturers’ and 
therefore reduced the specificity even further. Including ei-
ther ELISA in our routine practice would increase the num-
ber of false-positive results, which would need to be fur-
ther tested with a more specific assay. In this way, our aim 
of reducing the number of tests performed with FARR-RIA, 
while not missing any truly positive samples, would not be 
achieved. So, ELISAs are not used in our laboratory to de-
tect anti-dsDNA antibodies.
Recently, a similar study (18) compared FARR-RIA with 3 
commercial ELISAs and CLIFT. Their conclusion also con-
firmed  our  findings  that  the  FARR-RIA  assay  performed 
better than other assays and was the best assay to distin-
guish between patients with quiescent to mildly active SLE 
and patients with a more active type of SLE.
Having compared CLIFT, ELISA, and RIA, and considered 
both sensitivity and specificity, we conclude that greater 
sensitivity does not guarantee a larger number of truly 
positive samples. The major problem of anti-dsDNA ELI-
SAs represents nonspecific binding to the, plastic surface. 
However, their availability, ease of use, and quantitative 
output has kept ELISAs as methods of choice in many 
laboratories (26). An alternative to anti-dsDNA ELISAs and 
precoat problems are assays using biotinylated DNA and 
its streptavidin detection. This diminishes a lot of nonspe-
cific binding, as pointed out by Isenberg and Smeenk (27). 
The same authors stress the problems of different meth-
odologies, especially different sources of antigen, presen-
tation of the antigen to the antibodies, as well as condi-
tions of assay procedures. New generations of automated 
enzyme  immunoassays  (multiplex  assays  using  the  Lu-
minex 100 system consisting of distinct uniform 5.5 µm 
color-coded microspheres) and the latest assays (protein 
microarrays to detect immunologic targets) are now avail-
able, however they still need optimizations and extensive 
evaluation with FARR-RIA, CLIFT, and ELISA (10,27). In 2010, 
Antico et al (28) reported on new-generation immunoas-
says as an effective alternative to FARR-RIA technique and 
CLIFT. They examined 5 different tests: chemiluminescent 
immunoassay,  fluorometric  enzyme  immunoassay,  two 
classical ELISAs, CLIFT, and FARR. The conclusion was that, 
although tested on a limited number of samples, modern 
enzyme immunoassays for detecting anti-dsDNA antibod-
ies represented a valid alternative to FARR (28), and CLIFT 
could be used as a confirmatory test in enzyme immuno-
assay-positive sera.
There were also reports on a novel surface plasmon reso-
nance biosensor chip analytic method (29) and an inno-
vative quantitative electrochemical detection of anti-DNA 
antibodies (30). Just recently, a novel method using elec-
trophoretic mobility shift assay was reported by Keyhani 
et al (31), which showed in vivo and in vitro detections of 
a  complex  formation  between  plasma  membrane  DNA 
and IgG from SLE patients. However, more studies on larg-
er sample sizes need to be performed before these novel 
methods are introduced into routine practice.
Our study confirmed that we can decrease the use of FARR-
RIA with the introduction of CLIFT 2 assay and obtain the 
highest possible specificity and sensitivity. Since our origi-
nal intent was not to choose a screening test, but rather to 
perform a lower number of FARR-RIA tests, CLIFT 2 proved 
to be the optimal. Thus, considerably fewer sera need to 
be tested by FARR-RIA following the use of CLIFT 2 in order 
to quantify values and perform disease activity monitoring. 
In this way, we also decreased the time needed for report-
ing negative results, the amount of toxic, cancerogenous, 
and radioactive chemicals in the environment, and overall 
laboratory costs for anti-dsDNA testing. On the basis of all 
this, we recommend the use of CLIFT 2 followed by FARR-
RIA on positive samples, as well as finding a nonradioactive 
alternative to FARR-RIA.
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